Related Experiment Video

Updated: Mar 6, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

23.0K

Role of LRRK2 in physiological activities, diseases, and therapy

Zhuoran Wang1, Qingfang Li, Lingxi Yan

  • 1Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

Chinese Medical Journal
|March 5, 2026
PubMed

Insights

Leucine-rich repeat kinase 2 (LRRK2) is a key target for Parkinson's disease (PD) treatment. Inhibiting LRRK2 shows promise for PD therapy by correcting cellular issues and reducing neuronal damage.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Leucine-rich repeat kinase 2 (LRRK2) plays crucial roles in intracellular signaling, immune responses, and inflammation.
  • LRRK2 is implicated in both central nervous system and peripheral tissue functions.
  • Mutations in LRRK2 are associated with cellular dysfunction, including mitochondrial and neuronal damage, contributing to Parkinson's disease (PD) and other disorders.

Purpose of the Study:

  • To provide a comprehensive review of Leucine-rich repeat kinase 2 (LRRK2).
  • To analyze the physiological functions, disease involvement, and emerging therapeutic strategies related to LRRK2.
  • To highlight the importance of LRRK2 as a therapeutic target for Parkinson's disease.

Main Methods:

  • Literature review of LRRK2 research.
  • Analysis of LRRK2's role in cellular signaling and disease pathology.
  • Examination of current and potential therapeutic strategies targeting LRRK2.

Main Results:

  • LRRK2 kinase activity inhibition is a potential therapeutic strategy for PD.
  • Targeting LRRK2 may correct cellular imbalances and mitigate neuronal damage in PD.
  • Understanding LRRK2's molecular partners and tissue-specific functions is vital for targeted therapies.

Conclusions:

  • LRRK2 is a significant therapeutic target for Parkinson's disease and related disorders.
  • Further research into LRRK2's complex functions is essential for developing effective and safe treatments.
  • Targeted inhibition of LRRK2 offers a promising avenue for improving treatment options for neurological diseases.
Keywords:
Immune responseInflammation; Clinical trialInhibitorsIntracellular signalingLRRK2Novel targetsParkinson’s diseaseTargeted therapy

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.5K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

8.1K

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K